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Abstract: Vaccination is one of the most efficient tools for disease prevention, and a continuously
growing field of research. However, despite progress, we still need more efficient and cost-effective
vaccines that would improve access to those in need. In this review, we will describe the status
of virus-vectored vaccine technology with a focus on adenoviral-based vaccines. Adenovirus (Ad)
vaccines have proven to be efficient in military vaccinations against Ad4 and Ad7 and as highly
efficient vectored vaccines against rabies. The question of how other adenovirus-based vaccines can
become as efficient as the rabies vaccine is the underlying theme in this review. Here, we will first
give an overview of the basic properties of vectored vaccines, followed by an introduction to the
characteristics of adenoviral vectors and previously tested modifications of the vector backbone and
expression cassettes, with a focus on how they can contribute to increased vaccine cost-effectiveness.
Finally, we will highlight a few successful examples of research that have attempted to improve the
use of adenoviral-based vaccines by improving the transgene immunogenicity.
Keywords: adenovirus; vaccine; replication competent; transgene; affordable vaccine candidates;
protective immunity; vaccine technology platform; immune responses
1. Introduction
Vaccination has greatly reduced the burden of infectious diseases over the last 200 years, and clean
water is the only health intervention proven to perform better than vaccination to overcome sickness
and death [1]. Furthermore, vaccines have become of increasingly better quality and effectiveness [2],
and they hold a considerable safety advantage as compared to therapeutic medicines [3].
Despite these promising advancements, there is still a need for more cost-effective and also
long-lasting vaccine platforms. This is required in order to facilitate distribution to developing countries
and to facilitate veterinary prevention of infectious diseases, as opposed to antibiotic treatment or
mass culling when faced with serious infectious diseases.
The very first vaccine was the cowpox virus that was naturally attenuated in humans and could
provide cross-protective immunity against smallpox. This vaccine was dependent on the fortunate
availability of a related virus, but was highly effective and was the principal necessary tool in the
eradication of smallpox. After the discovery of vaccination with cowpox, Pasteur provided the
more generalizable principle of vaccination when he discovered that attenuation or inactivation of a
pathogen (in his case, anthrax and later rabies) could provide protection against the parental organism.
Several different types of vaccines have now been developed. These include: attenuated vaccines
rendering targeted microorganisms less toxic and dangerous (e.g., Bacillus Calmette-Guérin and
measles), and inactivated vaccines consisting of “killed” microorganisms rendered inoffensive for
the host (e.g., Vibrio cholerae or Yersinia pestis). Further attenuation can come from the use of subunit
vaccines which contain only a small fraction of the pathogen. In this case, immunity is based on
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the antigens requirement for inducing disease or infection (e.g., diphtheria toxin or hepatitis B virus
capsular antigen).
Unfortunately, while these approaches have steadily made vaccines safer, killed microorganisms
are not always able to trigger efficient immune responses, and toxoid vaccines usually do not trigger
long-lasting immune responses. The low cost of attenuated vaccines makes them an attractive
vaccination principle; however, such vaccines require the availability of an attenuated strain. Moreover,
attenuated vaccines present safety concerns, as they can potentially be harmful for the immune
deficient or may revert to wild type (WT) virulence [4].
While the initial vaccine technologies relied on the availability of methods to grow and administer
the pathogen in an immunogenic and safe manner, the field of vaccine development has experienced
major technological breakthroughs with the advent of recombinant vaccines based on scientific
knowledge and molecular biology. A highly versatile new category of vaccines are virus-vectored
vaccines, where the knowledge of different organisms allows you to combine the physiology of one
organism with the antigen of another. In principle, virus-vectored vaccines could be applied for
vaccination against any pathogen. Although acute viral infections tend to provide life-long immunity
from a single exposure, a number of limitations have prevented the emergence of vector-based
technologies as generalizable and cost-effective vaccination platforms. Different vector types have
been explored for vaccination purpose, including influenza virus, lentivirus, adeno-associated virus
and yellow fever virus. However, none of these have been found optimal for vaccination use, as they
are suboptimal either in stability, production, safety, immunogenicity, or cloning capacity. Finally,
adenovirus (Ad) and poxvirus vectors have been widely studied for some of the more challenging
antigens (e.g., human immunodeficiency virus (HIV)/malaria).
Both adenoviruses and poxviruses stand out, as they have been used in the most effective vaccine
delivery imaginable: replicating vaccinia or adenovirus-vectored vaccines against rabies delivered as
bait to wild animals. Adenovirus-based human vaccines have also been developed against adenovirus
type 4 and 7, administered as WT virus orally with enteric coating to military recruits to decrease
the number of acute respiratory diseases [5]. The military-specific vaccine showed efficiency as well
as long-lasting immunity, and was extremely safe with only 2/200,000 developing vaccine-related
symptoms [6]. Such a vaccine uses a safely replicating microorganism, delivered in the gut while
avoiding the lungs, where it would have caused pathology. Furthermore, it allows in situ dose
amplification (lowering production cost), offers easy administration, and leads to the induction of
mucosal immunity.
Interestingly, while both replicating poxviruses and adenoviruses have been produced and
encompass all the required qualities for an efficient and affordable vaccine, the experience from these
vaccines has not been generalized for use against other pathogens.
This review is about where we stand for development of generally applicable tools to design a
vaccine offering efficiency, safety, and longevity of protection, using the example of rabies vaccines.
We will first discuss the basic properties of vectored vaccines and, in particular, which properties of
the rabies vaccine make it so effective. Secondly, we will introduce the case of adenovirus vectors
as candidates that can fulfill all requirements for generalized effective vaccination. Finally, we will
present some examples where replication-competent adenoviruses have been modified in ways that
may render them more alike the rabies virus vaccine gold-standard.
2. Vectored Vaccines
2.1. Gold Standard, the Example of Rabies Vaccines
As mentioned before, two vectored vaccines against rabies are already in use and encompass all
the qualities required for a gold-standard vaccine. The first one is a vaccinia vectored rabies vaccine
from the poxvirus family. The construction of the vector was based on the backbone used to eradicate
smallpox, inserted with the rabies virus glycoprotein expressed from a poxvirus promoter. The vaccine
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is delivered orally by placing bait in the wild in order to immunize wildlife animals after ingestion.
The vaccinia rabies showed extraordinary results with the targeted species, as well as stability over
time and safety for nontargeted species [7]. Moreover, the use of this vaccine led to the elimination of
sylvatic rabies from large areas of land in Europe, meaning that vaccination was no longer needed [8].
The company, Artemis Technologies Inc., (Guelph, ON, Canada), has also manufactured an
adenovirus 5 for rabies vaccines, designed as a replication-competent human adenovirus type 5 vector
with the rabies virus glycoprotein gene inserted in the E3 region [9]. This new rabies vaccine is stable,
effective, and easily administered as bait by aerial distribution [10,11].
The adenovirus rabies vaccine has been tested for a number of wild life species (horses, pigs,
sheep, dogs, cats, chickens, meadow voles, foxes, cotton rats, squirrels, rabbits, groundhogs, and cows)
and has shown to be perfectly safe for all species and could trigger an antibody response against rabies,
in most cases after 28 days [12]. This replication-competent vaccine is effective and safe in animals
(also tested for safety in immunocompromised animals) after simple oral administration.
In support of this, several million inoculated bait samples have been distributed in Canada since
2006, and no public safety issue or serious human contact was reported, while local efficiency in
eradicating rabies has been described [13].
As the vaccinia vector presents some safety issues due to the incapacity to be sufficiently
attenuated for general use in humans, and is relatively poor at inducing T cells, adenoviruses
seem to offer some of the best prospects for a generally applicable vaccine platform. Notably, this
opinion is supported by the military vaccination campaign, as life-long immunity was induced after
single administration (type 4 and 7). The next chapter will be dedicated to a detailed description of
adenoviruses and their potential as generally applicable cost-effective vaccine vector candidates.
2.2. Lessons Learned from Non-Replicating Adenovirus-Vectored Vaccines
Adenoviruses have been studied as potential vaccine vectors since 1980 [14], and present some of
the best results available against cancer, SIV/HIV, herpes virus, papillomavirus, and a number of other
diseases [15].
Indeed, adenoviruses have the ability to be propagated to high-titer viral stocks [16],
well-established techniques exist for the construction of rAd vectors [17], and they have a well-
characterized genome [18,19]. Additionally, adenoviruses have broad cell tropism and can infect a
wide spectrum of dividing and nondividing cells with high efficiency of gene transfer [20]. They
also induce a potent cellular immune response to encoded antigens, with high numbers of antigens
delivered to the lymphoid tissues [21,22]. Moreover, they can encode relatively large DNA inserts
compared to many other vector types [23] and WT non-attenuated adenoviral infections are generally
without severe clinical symptoms [24].
The infectious cycle of adenoviruses can be divided into two phases. The early phase corresponds
to events occurring before initiation of genome amplification: entry of the virus into the host cell and
passage of the virus genome to the nucleus. This phase is controlled by the early genes: E1, E2, E3,
and E4. The E1 gene is required for inactivating the p53 and retinoblastoma genes and transactivates
the other viral promoters in cooperation with E4. E2 is responsible for genome replication, whereas
E3 contains host-specific immune-regulatory genes. The late phase includes assembly of the viral
particles in the nucleus and the maturation of infectious virions, and is encoded and controlled by the
late genes.
For the simple design of adenovirus-based vaccines, the insertion of foreign genes is based on the
deletion of early genes [25], which increases the capacity for inserting foreign antigens and attenuates
viral replication.
For safety reasons and convenience, most adenovirus vaccine candidates are E1 deleted, as E1
controls the other early genes, thus disabling the expression of early genes. This deletion prevents the
virus from spreading in the host and allows selection for recombinant viruses based on replicative
capacity in E1-expressing cell lines [26]. ∆E1 adenoviruses have now been used for vaccines in
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different species such as rodents, nonhuman primates, and humans. Studies have shown that the
prototypical replication-deficient adenovirus vector based on the human serotype 5 is well tolerated
and strongly immunogenic [27]. Intriguingly, in the case of non-replicative adenovirus vaccines,
transgene immunodominance might be facilitated, as the absence of genes controlling replication
reduces expression of most adenovirus encoded genes [28].
However, replication incompetence can only come at the price of lesser immunogenicity,
in particular, at low inoculation dosage, as the vaccine self-amplification in vivo is absent. Furthermore,
the incapacity of the replication deleted adenovirus to propagate in the host reduces the possibility of
reaching the lymphoid organs from mucosal immunization, leading to a requirement for dual route
immunization to induce both mucosal and systemic immune responses [29]. Yet, different insertion
sites can be considered (see Figure 1), thus offering different properties for the adenovirus vaccine.
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Figure 1. Different possibilit es of transgene insert t e adenoviral genome. The transgene can
be inserted in ifferent places in the adenoviral ge , thus offering diff rent characteristics to the
adenovirus vector. Transgene can be inserted in place of E3 gene, leaving E1 intact together with
the capacity of replication, which is the case for most replication-competent (RC), single cycle (SC),
and conditionally replicating (CRAd) adenoviruses. The transgene is usually inserted in place of
E1, thus preventing replication in the host as seen with first generation (FG). Gutless vectors only
contain the ITR domains of the adenovirus and are depleted of all adenoviral genes. These are also
called helper-dependent adenoviruses, as they require a helper virus to deliver the capsid genes
during production.
As mentioned before, ∆E1 adenoviruses are inherently suboptimal as vaccine candidates, thus an
affordable and cost-effective immunization platform must be based on replication-competent vectors.
3. Advantag of Replicatio -Competent Adenovirus Co par d to Oth r Adenovirus Vectors
Replication competent adenovirus (RCAd) can spread from their inoculation site, efficiently
priming responses after injection, and will amplify the originally administered vaccine inoculum.
This process can theoretically decrease the cost of the vaccine, as a low injection dose will still
allow the adenovirus to self-ex and in th host and trigger an immun response towards the in vivo
amplifi d inoculum.
The adenovirus type 5 vector, with th rabies glycoprotein inserted as a replacement of the E3
gene, is our defined gold-standard, and a lot of different studies have tested the vaccination potential
of RCAd against different types of antigens. In this section, we will present some examples showing
the capacity of RCAd to induce an efficient immune response against different transgenes.
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For vaccination against the HIV envelope, studies in mice revealed that high-capacity adenovirus
(HC, also named helper-dependent or gutless vector) [30], devoid of all adenovirus genes, could
elicit stronger antibody responses than first generation (FG) vectors [31]. However, in nonhuman
primates, where replication of human serotype 5 is possible, replication-competent (RC) vectors were
also superior in inducing antibodies and cellular immunity compared to FG vectors [32].
In both cases, it was or could be speculated that longer presentation of the transgene was the
reason for the improved immune responses. In mice, where all compared adenoviruses could not
replicate, the removed targets for vector elimination in HC vectors prolonged transgene expression and
facilitated the diversity of transgene directed responses [33]. In monkeys, replication competence of the
vector results in an extended transgene expression together with an ongoing infectious response [32,34].
The added benefit of robustly stimulating the innate immune system with an RC vector has the
disadvantage of the expression of all vectors’ genes and competition with the transgene for induction
of immune responses. Since the immunodominance of the vector genes over the transgene is already
a problem with FG vaccines [31,33], this problem can only be more pronounced in RC vaccines
(Figure 2C).
Despite competition from vector antigens, it appears that the replication competence may
still offer a net benefit. Transgene immunogenicity is likely the principal difference between RC
rabies vaccine and RC HIV vaccines, as FG rabies vaccine offer potent and long-lasting immune
responses after minute doses of adenovirus vaccine [35] (Figure 2A). Influenza-A vaccine, using
an envelope target of intermediate immunogenicity, has shown less impressive results when using
replication-competent adenoviruses (Figure 2B). For H5N1, RC adenovirus provided a response against
H5 in naïve individuals; however, it is expected that a protein boost would be required after priming
with RC adenovirus to elicit long-term memory and protection [36].
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Figure 2. Qualitative comparison of encoded transgene immunodominance as compared to
immunodominance induced by the adenoviral vector. Transgenes have different intrinsic
immunodominance that competes with different immunodominance of vector antigens in the
adeno iral vectors, thus influenci g the immune response [37]. As mentio ed before, rabies antigens
have a really high immunodomina ce (A) as co pared t HIV or influenza antigens. The adenoviral
vectors also influenc he tra sgene immunodominance offering a strong (B), mild (C), or low (D)
competition for the transgene. Thus, antigens like rabies might only require replication-competent
adenovirus, but HIV and influenza antigens probably require new adjuvant or other techniques for
increased immunodominance, particularly when delivered in replicating vectors.
These different studies have demonstrated greater efficiency and immunogenicity with RC
vectors than FG vaccin s, by inducing stronger cellular and humoral responses and conferring higher
protection, but without approaching the rabi s vaccine gold-standard. Whereas th majority of studies
are using relatively simple FG or RC adenovirus vector s stems, the comparison with complete virus
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gene-deleted vectors in mice (HC vectors) indicates that vector gene competition is an important
parameter [31,33] (Figure 2D). Essentially, the rabies vaccine is, in this review, hypothesized to work
by the combination of replication competence and transgene immunodominance. Accordingly, the
next two sections will focus on studies which have induced or are anticipated to be capable of
increasing transgene immunodominance, either by decreasing vector immunity or by increasing
transgene immunogenicity.
4. Induction of Transgene Immunodominance by Modulation of the Adenovirus
Vector Replication
An alternative to fully replication-competent E3-deleted adenoviruses is to selectively modulate
the replication capacities of the vector, by genetic mutation or deletion. As we will discuss, modulation
of the replication may in principal be used to lower the vector immunodominance as well as offer
some level of control over the spread of the adenovirus. Indeed, a major concern about using
replication-competent adenovirus is the potential loss of control over replication of the virus, and the
resulting potential for severe side-effects in immunocompromised individuals.
4.1. Cell- or Tissue-Specific Adenovirus Attenuation
Conditionally replicative adenoviruses (CRAds) have the ability to replicate, but only in a
restricted cell type or environment. The use of CRAds could be a crucial step into achieving a
cost-effective vaccine standard, as efficiency, safety, and cost-effective qualities potentially can be
combined in a single platform.
The classical example of virus attenuation is well established for live attenuated vaccines
and consists of temperature attenuation. Development of temperature-sensitive strains seems
perfectly doable for adenovirus vectors, but only limited testing for vaccination has been shown [38].
Limitation of virion production in replicative adenovirus is also another way of attenuating the
display and accessibility of the adenovirus capsid genes that will no longer be released from lysing
cells, while allowing stronger transgene responses from in situ amplified genomes. Single cycle
replication-competent adenoviruses (SC), deleted in the penton protein required for virion assembly,
have been studied for this purpose. Such viruses were demonstrated to be more immunogenic and
allowed a stronger and more persistent transgene expression and specific antibody response than
replication-deficient adenoviruses [39]. In the case of influenza, they showed that a 100-fold lower
dose of a single cycle replication-competent adenovirus was able to induce higher level of antibodies,
compared to replication deficient adenovirus [40].
To ensure a cell-specific replication profile, the E1 genes, responsible for expression of the early
genes, can be placed under the control of a cell-specific promoter, thus restricting the replication only
in a selected cell type. This method has been tested using a large range of different promoters, as the
promoter has to be chosen considering the vaccination route and the disease to target. As an example,
this method could in principle be applied to limit replication to specific cells such as epithelial cells
(e.g., allowing oral administration) or antigen-presenting cells.
CRAds have mostly been studied for cancer gene therapy, where the E1 gene is placed under the
control of a tumor-specific cell promoter (reviewed by Curiel in [41]), and have shown high specificity
in replication, but limited anticancer efficacy. Such viruses have been used to target and limit replication
to cancer cells and used the capacity of the virus to lyse and kill infected cells. Cell-specific inhibition
of replication or expression of virus genes have also been studied to a lesser extent, using cell-specific
miRNA, in the case of influenza A virus [42], hepatitis C virus [43], and also adenovirus [44].
Although, in the case of CRAds, the use of cell-specific replication can be used to lower the vector
immunogenicity and improve the safety of the vaccine, it is equally important to increase the expression
of the transgene (see Figure 3, which qualitatively depicts the differential expression of transgene
and vector for the different adenovirus candidates discussed in the review). It is noteworthy that in
the majority of RC adenovirus vaccines, the transgene expression is coupled to the virus replication
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and occurs from the E3 reading frame. As the E3 gene is turned on later than the E1 and E4 reading
frames, expression of the transgene through the E3 promoter [45] does not offer the most optimal
design for inducing transgene-specific immune responses. It is a testament to this consideration
that the most effective improvements of adenovirus immunogenicity have been the SC-adenovirus
vaccines, where a heterologous promoter was used to direct transgene expression. For fully RC
vaccines, it is of crucial importance to realize that the principle of (cell-specific) virus attenuation is
to limit vector replication, but it would be detrimental to simultaneously limit transgene expression.
As an example, temperature-sensitive adenovirus could replicate in the upper airways and reach
dendritic cells, but then suffer undesirable attenuation of transgene expression in antigen-presenting
cells in draining lymph nodes. The use of two different promoters to direct transgene expression
and replication as performed to track oncolytic viruses [46] or an exogenous promoter for antigen
in temperature-sensitive viruses would eliminate this problem. In this case, while replication of the
adenovirus would be limited to specific cells, the expression of the transgene will be extended to all
cells, ensuring a long-lasting presentation of the transgene to the immune system. This strategy could
promote a stronger immunodominance of the transgene over the vector, while keeping some of the
advantages of using replication-competent adenovirus, as described above.
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4.2. Increase of Transgene Immunodominance
Immunodominance of the transgene can in general be improved by using stronger
promoters [47–49] or by using specific adjuvants genetically linked to the transgene. As an example,
the invariant chain (II) of the MHCII was shown to be a surprisingly effective T cell inducer when used
as an adjuvant in the case of adenoviruses. Indeed, when the transgene was genetically coupled to the
invariant chain, it showed a consistent enhancement in CD8+ and CD4+ T cell responses as well as
longer-lasting immune responses [50–52]. Using the same strategy, the oligomerization domain of C4b
was also capable of increasing the T cell response against the transgene [53], as well as the antibody
response against malaria when used as an adjuvant in adenovirus vaccines [54].
T cell responses are usually quite high after adenovirus vaccination, though B cell responses
targeting the transgene might need to be improved after single adenoviral immunization. Indeed,
when the transgene is encoded in the adenoviral genome, it is mostly presented to the immune system
through MHCI; however, B cells are mostly activated after presenting the antigen to CD4+ T cells via
the MHCII. Different methods have increased the humoral response after incorporation of transgene
in to the different capsid proteins of the adenovirus compared to encoded antigen [55]. As hexon is
the most abundant capsid protein, it is expected that incorporation of antigens in the hexon protein
would yield the most antigen-specific immune responses [56]. Unfortunately, fiber and hexon only
allow incorporation of small peptides. However, pIX tolerates incorporation of large proteins, allowing
presentation of conformational antigens to the immune system, leading to a broader immune responses
as well as activation of conformational epitope for B cells’ activation [57]. The pIX immunogenicity can
further be improved by combination of display and transgene expression of antigen. This technique
has been taken quite far in the example of adenovirus that encoded and displayed antigen on the
surface of a replicating viral vaccine [58].
Increase of transgene-specific B cell responses can also be achieved by encoding virus-like
particles (VLPs) within the adenovirus genome and having these particles display the antigen. In this
case, the infected cell will produce VLPs that will present the transgene on their outer membrane.
Adenovirus-encoded VLPs—using SIV gag and a recombinant plasmodial antigen fused to a viral
envelope transmembrane tail—elicited an increased level of antibody responses and, most importantly,
showed better functionality of the induced antibodies [59]. This could potentially be explained by the
fact that conformational antigens are presented directly to B cells from secreted VLPs, thus resembling
a normal infection, and inducing conformational antibodies required for effective neutralization.
5. Conclusions
Knowledge about vaccine strategies has increased over the years and access to vaccination has
been enhanced around the world; this has permitted the extinction of some diseases. However, the
requirements for even better vaccines to fight more complex diseases (HIV, malaria, cancer) but also
for more accessible vaccines (low cost and easy administration) have not been met. Such vaccines exist
in particular cases (e.g., Ad4 and 7 in military recruits, rabies in wildlife), but tools for their generally
applicable development and use have not been established yet. In order to produce very affordable,
yet effective, vaccines, a requirement would be a cell-specific replicating vaccine which could increase
the recombinant transgene-directed immune response, as suggested to be possible by some studies.
Most importantly, with replicating vaccines, a low inoculation dose would confer sufficient immune
response due to amplification at the immunization site, while restricted replication only in targeted
cells or tissues would increase safety and potentially immune focus on the transgene. Conditionally
replicating adenoviruses also permit mucosal administration, offering mucosal immune responses
(required against most infectious diseases), as well as allowing easy administration through aerosol
sprays or tablets. Technologies may already exist to enable such improvements, but they have yet to
be combined and tested for vaccination approaches.
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